{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:01:50Z","timestamp":1789628510997,"version":"build-2803163510"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Ozanimod and etrasimod are sphingosine-1-phosphate receptor modulators approved for ulcerative colitis treatment. Given their limited real-world safety data in this specific population, we conducted a disproportionality analysis using the Food and Drug Administration Adverse Event (AE) Reporting System database, aiming to explore their post-marketing safety profile. Original data were extracted from the aforementioned database. Three algorithms, namely reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network, were employed to identify drug-related AE signals. We retrieved 1632 reports for ozanimod and 283 for etrasimod, with the most frequently reported age group being 50 to 59 years in both groups. At the system organ class level, signals for nervous system disorders, eye disorders, and cardiac disorders were detected for both drugs. At the preferred term level, 75 positive signals were identified for ozanimod and 24 for etrasimod. Common AEs for both drugs included drug ineffective, headache, dizziness, nausea, and blurred vision. Although most findings were consistent with the prescribing information, several unexpected AEs related to ozanimod merit special attention. The median onset time for ozanimod-related AEs was 17.5 days (interquartile range: 1.5\u201387.5 days). For etrasimod, the median onset time of AEs was 17.5 days (interquartile range: 2.75\u201369.25 days). We hope that these findings can provide comprehensive safety evidence for ozanimod and etrasimod, serving as a reference for clinicians in their individualized and safe application. However, due to the inherent limitations of the database, these findings still require further validation through prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050262","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:05:52Z","timestamp":1787331952000},"page":"e50262","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Safety of ozanimod and etrasimod in ulcerative colitis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2146-981X","authenticated-orcid":false,"given":"Long","family":"Chen","sequence":"first","affiliation":[{"name":"The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0615-6044","authenticated-orcid":false,"given":"Dongping","family":"Wan","sequence":"additional","affiliation":[{"name":"Postgraduate Education, Guangxi University of Chinese Medicine, Nanning, Guangxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benkai","family":"Xing","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Ji","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Zhou","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6993-9328","authenticated-orcid":false,"given":"Yongchao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine (Proctology Division), Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis.","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"R2-20260917","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis.","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"R5-20260917","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease.","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08830185.2025.2563522","article-title":"Revolutionizing IBD therapy: insights into contemporary treatment strategies.","volume":"45","author":"Kushwaha","year":"2026","journal-title":"Int Rev Immunol"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pharmthera.2015.11.011","article-title":"Small molecules with anti-inflammatory properties in clinical development.","volume":"157","author":"Hanke","year":"2016","journal-title":"Pharmacol Ther"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s40265-024-02094-5","article-title":"Targeting the sphingosine-1-phosphate pathway: new opportunities in inflammatory bowel disease management.","volume":"84","author":"Kitsou","year":"2024","journal-title":"Drugs"},{"key":"R9-20260917","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s43440-025-00725-6","article-title":"Lymphopenia associated with sphingosine 1-phosphate receptor modulators (S1PRMs) in multiple sclerosis: analysis of European pharmacovigilance data.","volume":"77","author":"Balzano","year":"2025","journal-title":"Pharmacol Rep"},{"key":"R10-20260917","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14656566.2023.2178898","article-title":"An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.","volume":"24","author":"Dumitrescu","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"R11-20260917","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/imm.12272","article-title":"Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond.","volume":"142","author":"Garris","year":"2014","journal-title":"Immunology"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40265-021-01528-8","article-title":"Targeting sphingosine-1-phosphate signaling in immune-mediated diseases: beyond multiple sclerosis.","volume":"81","author":"P\u00e9rez-Jeldres","year":"2021","journal-title":"Drugs"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00011-023-01829-6","article-title":"Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials.","volume":"73","author":"Suilik","year":"2024","journal-title":"Inflamm Res"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"R15-20260917","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis.","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cgh.2024.06.050","article-title":"Modern advanced therapies for inflammatory bowel diseases: practical considerations and positioning.","volume":"23","author":"Fudman","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/CEG.S391706","article-title":"Therapeutic potential of etrasimod in the management of moderately-to-severely active ulcerative colitis: evidence to date.","volume":"17","author":"Glassner","year":"2024","journal-title":"Clin Exp Gastroenterol"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"1376494","DOI":"10.3389\/fphar.2024.1376494","article-title":"Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"key":"R19-20260917","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.ajpc.2021.100171","article-title":"Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease.","volume":"6","author":"Agrawal","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/medicina62020270","article-title":"From inflammation to thrombosis: the prothrombotic state and cardiovascular risk in inflammatory bowel disease.","volume":"62","author":"Brata","year":"2026","journal-title":"Medicina (Kaunas)"},{"key":"R21-20260917","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.14309\/ajg.0000000000003673","article-title":"Inflammatory bowel disease and risk of more than 1,500 comorbidities: a disease-wide prediagnostic and postdiagnostic phenomic association study.","volume":"121","author":"Ebert","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"e100199","DOI":"10.1136\/egastro-2025-100199","article-title":"Clinical association between inflammatory bowel disease and primary sclerosing cholangitis: what changes after colectomy and liver transplantation?","volume":"3","author":"Wang","year":"2025","journal-title":"eGastroenterology"},{"key":"R23-20260917","doi-asserted-by":"crossref","first-page":"1446695","DOI":"10.3389\/fmed.2025.1446695","article-title":"Interprofessional approach to personalized medication management and therapy optimization in IBD care.","volume":"12","author":"Fleischmann","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"R24-20260917","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis.","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"R25-20260917","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE study.","volume":"15","author":"Sandborn","year":"2021","journal-title":"J Crohns Colitis"},{"issue":"Suppl 1","key":"R26-20260917","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.14309\/01.ajg.0000722920.48091.e7","article-title":"P031 ozanimod in patients with moderate-to-severe ulcerative colitis: long-term safety and efficacy from the phase 2 TOUCHSTONE study 4-year open-label extension.","volume":"115","author":"William","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"R27-20260917","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ecco-jcc\/jjad146","article-title":"Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the true north open-label extension.","volume":"18","author":"Danese","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R28-20260917","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis.","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"R29-20260917","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjae007","article-title":"Achievement of clinical, endoscopic, and histological outcomes in patients with ulcerative colitis treated with etrasimod, and association with faecal calprotectin and C-reactive protein: results from the phase 2 OASIS trial.","volume":"18","author":"Yarur","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R30-20260917","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/ecco-jcc\/jjab016","article-title":"Long-term safety and efficacy of etrasimod for ulcerative colitis: results from the open-label extension of the OASIS study.","volume":"15","author":"Vermeire","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R31-20260917","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ibd\/izad120","article-title":"Safety and monitoring of inflammatory bowel disease advanced therapies.","volume":"30","author":"Bhat","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R32-20260917","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis.","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"key":"R33-20260917","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/ijc.34848","article-title":"Ocular toxicity associated with anti-HER2 agents in breast cancer: a pharmacovigilance analysis using the FAERS database.","volume":"154","author":"Chen","year":"2024","journal-title":"Int J Cancer"},{"key":"R34-20260917","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13058-025-02013-w","article-title":"Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database.","volume":"27","author":"Han","year":"2025","journal-title":"Breast Cancer Res"},{"key":"R35-20260917","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"R36-20260917","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"R37-20260917","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-024-01669-4","article-title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA adverse event reporting system database.","volume":"17","author":"Xing","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"R38-20260917","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting.","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R39-20260917","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation.","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"R40-20260917","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease.","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut"},{"key":"R41-20260917","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.3390\/biomedicines10071735","article-title":"Sphingosine 1-phosphate modulation in inflammatory bowel diseases: keeping lymphocytes out of the intestine.","volume":"10","author":"Dal Buono","year":"2022","journal-title":"Biomedicines"},{"key":"R42-20260917","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjae038","article-title":"Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: results from the phase 3 ELEVATE UC clinical programme.","volume":"18","author":"Peyrin-Biroulet","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R43-20260917","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1124\/pr.107.07113","article-title":"\u201cInside-out\u201d signaling of sphingosine-1-phosphate: therapeutic targets.","volume":"60","author":"Takabe","year":"2008","journal-title":"Pharmacol Rev"},{"key":"R44-20260917","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/2211-5463.13907","article-title":"Unique pharmacological properties of etrasimod among S1P receptor modulators.","volume":"15","author":"Gaidarov","year":"2025","journal-title":"FEBS Open Bio"},{"key":"R45-20260917","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/ibd\/izy269","article-title":"Cell trafficking interference in inflammatory bowel disease: therapeutic interventions based on basic pathogenesis concepts.","volume":"25","author":"P\u00e9rez-Jeldres","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"R46-20260917","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrd4099","article-title":"Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.","volume":"12","author":"Kunkel","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"R47-20260917","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2024.2402931","article-title":"Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis.","volume":"20","author":"Vieujean","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R48-20260917","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease.","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun Rev"},{"key":"R49-20260917","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","article-title":"Modulation of sphingosine-1-phosphate in ulcerative colitis.","volume":"20","author":"Argollo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"R50-20260917","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3390\/jcm12155014","article-title":"Efficacy and safety of S1P1 receptor modulator drugs for patients with moderate-to-severe ulcerative colitis.","volume":"12","author":"Bencardino","year":"2023","journal-title":"J Clin Med"},{"key":"R51-20260917","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ecco-jcc\/jjad112","article-title":"Clinician\u2019s guide to using ozanimod for the treatment of ulcerative colitis.","volume":"17","author":"Sands","year":"2023","journal-title":"J Crohns Colitis"},{"key":"R52-20260917","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ueg2.12559","article-title":"A Gastroenterologist\u2019s guide to drug interactions of small molecules for inflammatory bowel disease.","volume":"12","author":"Harnik","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"R53-20260917","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.3390\/jcm13247534","article-title":"Sex-based disparities in treatment and healthcare utilization in patients with ulcerative colitis: a systematic review and meta-analysis.","volume":"13","author":"Shah","year":"2024","journal-title":"J Clin Med"},{"key":"R54-20260917","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/MIB.0000000000000738","article-title":"Epidemiology and long-term outcome of inflammatory bowel disease diagnosed at elderly age-an increasing distinct entity?","volume":"22","author":"Jeuring","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"R55-20260917","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0018578719882323","article-title":"Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength.","volume":"56","author":"Neha","year":"2021","journal-title":"Hosp Pharm"},{"key":"R56-20260917","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/jcph.887","article-title":"Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator.","volume":"57","author":"Tran","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"R57-20260917","doi-asserted-by":"crossref","first-page":"104469","DOI":"10.1016\/j.drudis.2025.104469","article-title":"Clinical status and CNS adverse drug report of sphingosine-1-phosphate receptor modulators in multiple sclerosis.","volume":"30","author":"Haldar","year":"2025","journal-title":"Drug Discov Today"},{"key":"R58-20260917","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.dld.2024.03.010","article-title":"Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus.","volume":"56","author":"Olivera","year":"2024","journal-title":"Dig Liver Dis"},{"key":"R59-20260917","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.cgh.2023.11.018","article-title":"Cardiovascular safety of ozanimod in patients with ulcerative colitis: true north and open-label extension analyses.","volume":"22","author":"Armuzzi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R60-20260917","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","article-title":"Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.","volume":"168","author":"Camm","year":"2014","journal-title":"Am Heart J"},{"key":"R61-20260917","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-021-01057-z","article-title":"Safety of S1P modulators in patients with immune-mediated diseases: a systematic review and meta-analysis.","volume":"44","author":"Lasa","year":"2021","journal-title":"Drug Saf"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:02:05Z","timestamp":1789624925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050262"}},"subtitle":["A disproportionality analysis of the Food and Drug Administration Adverse Event Reporting System database"],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":61,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050262","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2025-09-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}